- CEO
- Shigeyuki Kawamura
- Full Time Employees
- 5,946
- Sector
- Process industries
- Industry
- Chemicals: major diversified
- Address
- Meiji Yasuda Seimei Building Tokyo TY Japan 100-0005
- IPO Date
- May 16, 1949
- Business
- Nippon Kayaku Co., Ltd. manufactures and sells functional chemicals, pharmaceuticals, and safety systems. The company operates through three main segments: the Mobility and Imaging Business Area, which provides airbag inflators, micro gas generators for seatbelt pretensioners, squibs, dye-type polarizers for projectors and vehicles, and components for X-ray analysis systems including rare metals detectors; the Fine Chemicals Business Area, which offers resins for semiconductors, UV-curing resins, resist materials for MEMS, agrochemicals, color materials such as industrial inkjet inks and developers for thermal paper, and other high-performance materials for electronics; and the Life Science Business Area, which develops and markets oncology drugs and other specialized pharmaceuticals. Founded in 1916 and headquartered in Chiyoda-ku, Tokyo, Japan, Nippon Kayaku serves global markets including Asia, Europe, and North America through subsidiaries such as Kayaku Safety Systems Europe a.s., Kayaku Safety Systems (Huzhou) Co., Ltd., and RaySpec Ltd. In August 2025, the company executed a shareholders agreement with Formiica Pharmaceuticals Pte. Ltd. and CBC Co., Ltd. to establish a Singapore-based joint venture for in-licensing and sublicensing pharmaceutical products into Asia and Oceania, granting Nippon Kayaku preferential rights for Japan to bolster its domestic operations. In November 2025, Nippon Kayaku launched IBTROZI Capsules 200mg (taletrectinib adipate), an in-licensed oncology medicine from Nuvation Bio Inc. for ROS1 fusion gene-positive unresectable advanced and/or recurrent non-small cell lung cancer, marking its entry into next-generation targeted therapies. The company also completed a treasury stock acquisition of approximately 6.59 million shares in September 2025 as part of its capital management strategy.